Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Harmony Biosciences Holdings, Inc. - Common Stock
(NQ:
HRMY
)
35.85
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Harmony Biosciences Holdings, Inc. - Common Stock
< Previous
1
2
Next >
Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
February 10, 2026
From
Harmony Biosciences Holdings, Inc.
Via
Business Wire
Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 07, 2026
From
Harmony Biosciences Holdings, Inc.
Via
Business Wire
Beacon Biosignals Announces Partnership with Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative EEG
December 16, 2025
From
Beacon Biosignals
Via
GlobeNewswire
Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome
December 08, 2025
From
Harmony Biosciences Holdings, Inc.
Via
Business Wire
Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting
December 02, 2025
From
Harmony Biosciences Holdings, Inc.
Via
Business Wire
Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation
November 24, 2025
From
Harmony Biosciences Holdings, Inc.
Via
Business Wire
Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence
November 19, 2025
From
Harmony Biosciences Holdings, Inc.
Via
Business Wire
Harmony Biosciences to Participate in Upcoming Investor Conferences
November 18, 2025
From
Harmony Biosciences
Via
Business Wire
Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M
November 04, 2025
From
Harmony Biosciences Holdings, Inc.
Via
Business Wire
Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance
October 23, 2025
From
Harmony Biosciences Holdings, Inc.
Via
Business Wire
Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome
September 24, 2025
From
Harmony Biosciences Holdings, Inc.
Via
Business Wire
Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress
August 26, 2025
From
Harmony Biosciences Holdings, Inc.
Via
Business Wire
Harmony Biosciences to Participate in 2025 Cantor Global Healthcare Conference
August 21, 2025
From
Harmony Biosciences Holdings, Inc.
Via
Business Wire
Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025
August 05, 2025
From
Harmony Biosciences Holdings, Inc.
Via
Business Wire
Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025
July 22, 2025
From
Harmony Biosciences Holdings, Inc.
Via
Business Wire
Harmony Biosciences to Participate in H.C. Wainwright "HCW@Home" Series
July 15, 2025
From
Harmony Biosciences
Via
Business Wire
Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025
June 11, 2025
From
Harmony Biosciences Holdings, Inc.
Via
Business Wire
Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation
June 05, 2025
From
Harmony Biosciences Holdings, Inc.
Via
Business Wire
Harmony Biosciences to Participate in Goldman Sachs 46th Annual Global Healthcare Conference
June 04, 2025
From
Harmony Biosciences Holdings, Inc.
Via
Business Wire
Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance
May 06, 2025
From
Harmony Biosciences Holdings, Inc.
Via
Business Wire
Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025
April 29, 2025
From
Harmony Biosciences Holdings, Inc.
Via
Business Wire
Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome
April 08, 2025
From
Harmony Biosciences Holdings, Inc.
Via
Business Wire
Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors
April 03, 2025
From
Harmony Biosciences Holdings, Inc.
Via
Business Wire
Harmony Biosciences to Participate in 24th Annual Needham Virtual Healthcare Conference
March 26, 2025
From
Harmony Biosciences Holdings, Inc.
Via
Business Wire
Harmony Biosciences Names Adam Zaeske as Chief Commercial Officer to Lead the Next Phase of Commercial Growth as Its Portfolio Expands
March 24, 2025
From
Harmony Biosciences Holdings, Inc.
Via
Business Wire
HRMY Investors Have Opportunity to Join Harmony Biosciences Holdings, Inc. Fraud Investigation with the Schall Law Firm
March 21, 2025
From
The Schall Law Firm
Via
Business Wire
Harmony Biosciences to Participate in Upcoming Investor Conferences
March 04, 2025
From
Harmony Biosciences Holdings, Inc.
Via
Business Wire
Harmony Biosciences Reports Strong 2024 Financial Results and Reiterates 2025 Net Revenue Guidance; Highlights 2025 Catalysts in Sleep/Wake and Fragile X Syndrome Development Programs
February 25, 2025
From
Harmony Biosciences Holdings, Inc.
Via
Business Wire
Harmony Biosciences Provides Update on the Status of the Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia
February 19, 2025
From
Harmony Biosciences Holdings, Inc.
Via
Business Wire
Harmony Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
February 18, 2025
From
Harmony Biosciences Holdings, Inc.
Via
Business Wire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
